PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2018 Jun 7

PMID 29871906

Citations 20

Authors

Panagiotis A Konstantinopoulos

Ursula A Matulonis

Affiliations

Soon will be listed here.

Abstract

PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and -mutated (m) cancer treatment. .

Citing Articles

Improving olaparib exposure to optimize adverse effects management.

Sterle M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S Ther Adv Med Oncol. 2024; 16:17588359241248328.

PMID: 38665845 PMC: 11044803. DOI: 10.1177/17588359241248328.

Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Chen J, Wu X, Wang H, Lian X, Li B, Zhan X Curr Comput Aided Drug Des. 2023; 20(6):736-751.

PMID: 37691198 DOI: 10.2174/1573409920666230907093331.

Partial response to niraparib in combination with tislelizumab in a patient with metastatic undifferentiated tonsillar carcinoma: a case report and literature review.

Zhang J, Dai Z, Liao P, Guan J Front Oncol. 2023; 13:1078814.

PMID: 37274279 PMC: 10234503. DOI: 10.3389/fonc.2023.1078814.

Emerging roles of m6A RNA modification in cancer therapeutic resistance.

Liu W, Zhang Z, Wang F, Wang H Exp Hematol Oncol. 2023; 12(1):21.

PMID: 36810281 PMC: 9942381. DOI: 10.1186/s40164-023-00386-2.

High Expression of in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer.

Zuo W, Zhao C, Li Y, Sun H, Ma G, Liu Y Front Oncol. 2022; 12:931445.

PMID: 35875162 PMC: 9301997. DOI: 10.3389/fonc.2022.931445.